StocksMedium•18 November 2026•
1 min read
Omeros Upgraded to Speculative Buy Following 26% Sequential Growth in Yartemlea Sales
Key Facts
1Omeros stock was upgraded to 'Speculative Buy' driven by strong commercial momentum for Yartemlea.
2Q3 net product revenue rose 26% sequentially to $35.9 million.
3The U.S. model values Yartemlea at $870.6 million with peak annual sales projected at $350 million.
Omeros Corporation stock was upgraded to a 'Speculative Buy' rating driven by strong commercial momentum for its drug Yartemlea. Seeking Alpha reported that Q3 net product revenue rose 26% sequentially to reach $35.9 million, reflecting a successful launch phase for the treatment.
The U.S. market model values Yartemlea at approximately $870.6 million, with peak annual sales projected to reach $350 million. OMER closed at $13.92 on November 17, 2026, having traded between a low of $12.7 and a high of $14.65 during that session.